Network for vaccine development
VACCELERATE provides expertise, services, resources and solutions to accelerate existing and upcoming development programmes and market approvals for new vaccines and vaccination strategies.
The network serves as a single point of contact for all parties involved in COVID-19 vaccine development (pharmaceutical companies, academia, European Commission, EMA, ECDC, national health authorities and others) for Phase 2 and Phase 3 trials in Europe. The network addresses all research questions of interest, e.g. vaccine efficacy in different virus variants, studies in children, pregnant women, immunocompromised patients, studies on the combination of different vaccines, etc.
The establishment of a European volunteer registry for vaccine trials enables fast and efficient recruitment of trial participants (more than 37,000 volunteers in 15 countries: Austria, Belgium, Cyprus, Czech Republic, Germany, Greece, Ireland, Israel, Italy, Lithuania, Norway, Portugal, Spain, Sweden, Turkey; expansion to other countries is in preparation).
‘Thinking, acting and researching globally will get us there faster. A pandemic like the one COVID-19 has brought us clearly shows how important joint, targeted action is.’